Ken Ogasawara
About Ken Ogasawara
Ken Ogasawara is the Director of Clinical Pharmacology and Pharmacometrics at Bristol Myers Squibb in Summit, New Jersey.
Title
Ken Ogasawara currently serves as the Director of Clinical Pharmacology and Pharmacometrics at Bristol Myers Squibb in Summit, New Jersey, United States.
Current Role at Bristol Myers Squibb
Ken Ogasawara oversees clinical pharmacology and pharmacometrics as a Director at Bristol Myers Squibb. His role emphasizes optimizing drug development processes and ensuring efficient data analysis and interpretation in clinical studies.
Former Roles at Bristol Myers Squibb
Before his current position, Ken held multiple roles at Bristol Myers Squibb. He was an Associate Director from 2020 to 2021, contributing to the clinical pharmacology and pharmacometrics division. He also served as Principal Scientist from 2019 to 2020, focusing on data analysis and drug development strategies.
Experience at Celgene
Ken worked at Celgene as a Principal Scientist for a brief period in 2019, after serving as a Senior Scientist from 2018 to 2019. In these roles, he contributed to the advancement of clinical pharmacology through various research initiatives in the Greater New York City Area.
Academic and Regulatory Background
Ken's academic and regulatory experiences include a fellowship at the FDA's Division of Quantitative Methods and Modeling, where he worked for 11 months. He also held postdoctoral research roles at the University of Rhode Island and Medical College of Georgia, as well as conducting research as a fellow at the Japan Society for the Promotion of Science.
Education and Expertise
Ken holds a Master of Public Health (MPH) from Johns Hopkins Bloomberg School of Public Health, which he completed in 2017. He earned his Ph.D. and B.S. in Pharmaceutical Sciences from Kyoto University, demonstrating a solid foundation in the field. His educational background supports his expertise in clinical pharmacology and pharmacometrics.